Data Year:

For its 2024 fiscal year, BEONE MEDICINES LTD, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
John V. Oyler
Co-Founder, Chairman and Chief Executive Officer
Total Compensation $20,836,439 View details Pay Rank By Title In Biotechnology industry #19 View more
Xiaobin Wu
President, Chief Operating Officer and General Manager, China
Total Compensation $11,138,093 View details Pay Rank By Title In Biotechnology industry #6 View more
Lai Wang
Global Head of R&D
Total Compensation $7,402,451 View details Pay Rank By Title In Biotechnology industry #2 View more
Julia Wang
Former Chief Financial Officer
Total Compensation $10,324,537 View details Pay Rank By Title In Biotechnology industry #4 View more
Chan Lee
Senior Vice President, General Counsel
Total Compensation $4,676,148 View details Pay Rank By Title In Biotechnology industry #10 View more
Aaron Rosenberg
Chief Financial Officer
Total Compensation $6,150,178 View details Pay Rank By Title In Biotechnology industry #34 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at BEONE MEDICINES LTD as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. BEONE MEDICINES LTD income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. BEONE MEDICINES LTD annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
John V. Oyler
Co-Founder, Chairman and Chief Executive Officer
Total Cash $2,640,000 Equity $17,999,692 Other $196,747 $20,836,439
Xiaobin Wu
President, Chief Operating Officer and General Manager, China
Total Cash $1,621,505 Equity $9,299,898 Other $216,690 $11,138,093
Lai Wang
Global Head of R&D
Total Cash $1,124,297 Equity $6,199,798 Other $78,356 $7,402,451
Julia Wang
Former Chief Financial Officer
Total Cash $620,000 Equity $8,194,337 Other $1,510,200 $10,324,537
Chan Lee
Senior Vice President, General Counsel
Total Cash $1,055,700 Equity $3,599,748 Other $20,700 $4,676,148
Aaron Rosenberg
Chief Financial Officer
Total Cash $1,140,800 Equity $4,999,839 Other $9,539 $6,150,178
For its 2024 fiscal year, BEONE MEDICINES LTD, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
John V. Oyler CEO Pay $20,836,439 Median Employee Pay $88,543 CEO Pay Ratio 235:1
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.